Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases
Funds clinical testing research for rare neurodegenerative disorders and therapeutic development.
The FDA Rare Neurodegenerative Disease Grants Program was established by the ACT for ALS Act of 2021 and has been active since 2022. Administered by the FDA Office of Orphan Products Development, the program funds clinical trials of interventions intended to prevent, diagnose, mitigate, treat, or cure amyotrophic lateral sclerosis (ALS) and other rare neurodegenerative diseases in both adults and …
Clinical trials of interventions to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in adults and children, funded under the ACT for ALS Act of 2021.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see the timeline
Sign up free to see where teams trip up